Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | £227 | £159 | £1,643 | £1,248 |
| Short-Term Investments | £0 | £0 | £0 | £0 |
| Receivables | £343 | £8 | £828 | £5 |
| Inventory | £0 | £0 | £0 | £0 |
| Other Curr. Assets | £0 | £0 | £0 | £0 |
| Total Curr. Assets | £570 | £839 | £2,471 | £2,170 |
| Property Plant & Equip (Net) | £2,193 | £2,727 | £3,007 | £3,312 |
| Goodwill | £0 | £0 | £0 | £0 |
| Intangibles | £182 | £477 | £473 | £441 |
| Long-Term Investments | £0 | £0 | £0 | £0 |
| Tax Assets | £0 | £0 | £0 | £0 |
| Other NC Assets | £157 | £168 | £166 | £182 |
| Total NC Assets | £2,531 | £3,373 | £3,646 | £3,936 |
| Other Assets | £0 | £0 | £0 | £0 |
| Total Assets | £3,101 | £4,212 | £6,116 | £6,106 |
| Liabilities | – | – | – | – |
| Payables | £909 | £683 | £309 | £302 |
| Short-Term Debt | £414 | £424 | £256 | £273 |
| Tax Payable | £0 | £0 | £0 | £0 |
| Deferred Revenue | £0 | £0 | £0 | -£0 |
| Other Curr. Liab. | -£414 | -£372 | -£256 | -£273 |
| Total Curr. Liab. | £1,323 | £1,159 | £564 | £652 |
| LT Debt | £0 | £0 | £0 | £0 |
| Deferred Rev, NC | £0 | £0 | £0 | £0 |
| Deferred Tax Liab, NC | £0 | £0 | £0 | £0 |
| Other NC Liab. | £535 | £0 | £0 | £0 |
| Total NC Liab. | £2,325 | £2,199 | £2,529 | £2,673 |
| Other Liabilities | £0 | £0 | £0 | £0 |
| Cap. Leases | £2,203 | £2,623 | £2,784 | £2,673 |
| Total Liabilities | £3,648 | £3,358 | £3,093 | £3,325 |
| Equity | – | – | – | – |
| Pref Stock | £0 | £0 | £0 | £0 |
| Common Stock | £14,029 | £35 | £13,418 | £11,756 |
| Retained Earnings | -£40,586 | -£35,582 | -£26,618 | -£23,805 |
| AOCI | £3,130 | £1,073 | £985 | -£5,071 |
| Other Equity | £0 | £8,898 | -£6,158 | £0 |
| Total Equity | -£500 | £898 | £3,064 | £2,819 |
| Supplemental Information | – | – | – | – |
| Minority Interest | -£46 | -£44 | -£40 | -£38 |
| Total Liab. & Tot. Equity | £3,101 | £4,212 | £6,116 | £6,106 |
| Net Debt | £187 | £264 | -£1,387 | -£975 |